CDMO News news

• 6 January 2025

  MSD Ireland to Acquire WuXi Vaccines' Dundalk Facility

  The acquisition involves a €500M investment, adding 1,000 jobs across Ireland by 2025, enhancing vaccine production capabilities and strengthening Ireland's pharma sector.
• 

  6 December 2024

  WuXi Biologics Hits Key Milestones at Ireland Site with 16,000L PPQ Success and HPRA GMP Approvals

  The Dundalk site completed two successful PPQ runs and received GMP approval, enhancing its role in global biomanufacturing with innovative, sustainable processes and strong regulatory compliance.
• 

  6 November 2024

  Tosoh Bioscience Expands European HQ in Germany

  The expanded HQ features advanced labs and training areas for chromatography, enhancing customer collaboration and innovation in biomolecule and polymer analysis.
• 

  7 October 2024

  PCI Pharma invests $365M in EU and US facilities for advanced drug delivery and device products

  Investments enhance drug-device assembly, packaging, and storage in the US and EU, focusing on injectables and biologics, with new facilities in Illinois and Ireland.
• 

  21 September 2024

  Lilly Invests $1.8 Billion in Irish Manufacturing Expansion

  The $1.8B investment will boost production of Alzheimer's, diabetes, and obesity treatments, create 150 jobs, and enhance sustainability with advanced technologies and a solar farm.
• 

  28 June 2024

  EuroAPI FOCUS-27 Plan: Job Cuts and Facility Divestments

  The FOCUS-27 plan aims to boost competitiveness with €110-120M restructuring costs, €350-400M CAPEX, and €75-80M annual EBITDA by 2027, focusing on high-value APIs and strategic sites.

• 

  3 June 2024

  WACKER Launches mRNA Center in Halle, Germany

  The new facility in Halle enables large-scale mRNA production, creating over 100 jobs and supporting Germany's pandemic preparedness with a capacity for 200 million vaccine doses annually.
• 

  5 April 2024

  Pantherna and WACKER Expand mRNA Biopharmaceutical Collaboration

  WACKER's Halle site will produce mRNA-based ARDS treatment using a scalable process. The facility, operational by mid-2024, marks a milestone in their collaboration with Pantherna.
• 

  13 February 2024

  PanTera and Bayer Sign Actinium-225 Supply Agreement

  Starting in late 2024, PanTera will supply actinium-225, enhancing access for clinical trials and developing a large-scale production facility to meet global demand for radiopharma-based cancer treatments.
• 

  10 November 2023

  Novo Nordisk to Invest €5.6 Billion in Expanding Danish Manufacturing Facilities

  The €5.6 billion investment will expand API and packaging capacity, create 800 jobs, and enhance sustainability. Completion is expected between 2025-2029, with 3,000 external workers during construction.
• 

  13 October 2023

  Lonza to Add New ADC Filling Line at Stein Facility

  The new cGMP filling line will enhance bioconjugate handling and create 115 jobs by 2027, expanding end-to-end ADC manufacturing capabilities and supporting clinical and commercial supply.
• 

  12 June 2023

  Novo Nordisk to Invest €2.1bn in Danish Manufacturing Expansion

  The €2.1bn investment will expand API production in Hillerød, creating 340 jobs by 2029. The facility will enhance production capacity, flexibility, and sustainability for future chronic disease treatments.
• 

  8 May 2023

  WACKER Acquires ADL Biopharma to Boost Biotechnology Business

  The acquisition expands fermentation capacity by 2,000 cubic meters, enhances recovery and purification processes, and aims to grow customer relationships in food, pharmaceutical, and consumer goods sectors.
• 

  29 March 2023

  Lonza Expands Drug Product Manufacturing in Visp

  The new cGMP line in Visp is operational, with first batches in April 2023. It supports clinical and commercial needs, enhancing end-to-end solutions and complementing recent site expansions.
• 

  9 March 2023

  Sandoz to Build New Biologics Plant in Slovenia

  The $400M investment aims to boost biosimilar production, with operations starting in 2026. This supports the company's growth in biosimilars and antibiotics, enhancing access to critical medicines.
• 

  16 February 2023

  Lonza Expands Bioconjugation Facility in Visp

  The expansion includes two new manufacturing suites, enhancing capabilities for clinical and commercial supply, and increasing process, analytical development, and quality control capacity.
• 

  1 July 2022

  Lonza to Build Large-Scale Drug Product Facility in Stein

  The CHF 500M facility, set for 2026 completion, will enhance end-to-end drug product manufacturing, leveraging existing infrastructure and focusing on sustainability with a photovoltaic roof.
• 

  18 November 2021

  Arxada Invests CHF 20m in Czech Biotech Plant

  The investment will enhance infrastructure, expand technological options, and increase formulation capacity to support a growing customer base and accelerate project development.
• 

  24 August 2020

  Eurofins Expands Chemistry Capacity for Drug Discovery Market

  A new 63,000 sq ft facility in Murcia, Spain, will double current capacity for chemical synthesis and purification, supporting growth and providing new services. Completion is expected by early 2021.
• 

  28 July 2020

  WACKER Expands Amsterdam Biotech Facility

  Investing in new fermentation lines and cleanroom upgrades, the Amsterdam site will enhance production of biologics, LMPs, and vaccines, supporting growth in the pharmaceutical market.
• 

  7 April 2020

  AGC Expands Spanish Pharmaceutical Production

  The expansion will boost production capacity by 1.3 times and add a new R&D facility. This aligns with AGC's strategy to grow its life-sciences business and meet rising demand in the pharmaceutical CDMO market.
• 

  4 February 2020

  WeylChem Invests in Allessa Multi-Purpose Plant

  WeylChem is upgrading its Frankfurt Fechenheim plant to enhance its HALEX technology, driven by customer demand. The new plant will be operational in H2 2021, alongside a new SAP S/4 Hana system.
• 

  22 November 2019

  WuXi Vaccines to Invest $240M in New Ireland Facility

  The new facility in Dundalk will create 200 jobs, produce vaccines for a global pharma, and enhance Ireland's life sciences ecosystem, pending planning approval.
• 

  11 September 2019

  Merz and Oncotec Invest in Dessau BioPharmaPark

  Merz opens a new filler plant, while Oncotec unveils a robot-controlled filling line and visual inspection system, marking significant investments and expansions at Dessau BioPharmaPark.
• 

  28 March 2019

  Merck Expands Biotech Manufacturing Capacity

  €150M investment in Aubonne, Switzerland, for new building with advanced tech to boost production of biotech medicines, meeting global demand. Completion expected by 2023.
• 

  14 January 2019

  Cerbios Expands High Potency API Manufacturing

  A new production line for larger volumes and batch sizes will be added, enhancing capacity for HPAIs and CDMO services, with completion expected in the second half of 2020.
• 

  8 January 2019

  Almac Group Adopts Continuous Flow Technology

  The company expands its API services with continuous flow technology, enhancing product quality, process safety, and efficiency. A 4-year strategy focuses on advanced synthesis methods.
• 

  5 December 2018

  WuXi Biologics Begins Building Major Biomanufacturing Facility in Ireland

  Construction starts on a new facility in Dundalk, Ireland, featuring advanced bioprocessing technology and supported by the Irish Government, enhancing global biomanufacturing capabilities.